ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

RO7875913

A development code.

Its studies are mostly in Multiple Myeloma, led by Hoffmann-La Roche.

Furthest: phase 1, since Jan 6, 20261 company-led study, 1 open or runningNext primary completion: Jun 17, 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche11 open or runningphase 1since Jan 6, 2026Jan 6, 2026Jun 17, 2030phase 1 · NCT07342114

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 6, 2026First study: phase 1 study in Multiple MyelomaFirst studyNCT07342114 · 240 enrolled · New Zealand

Ahead

  1. Jun 17, 2030Primary completion: phase 1 study in Multiple MyelomaNCT07342114

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07342114Multiple Myeloma · New Zealand1Active, not recruitingJun 17, 2030240

How it is read

Names in the registry

  • “RO7875913”, 1 entry

Codes read as this program: RO7875913.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.